Expert Analysis of New Data From APLAR, EULAR, and JCR 2019
  • CME

APLAR 2019: Brisbane, Australia; April 8-11, 2019; JCR: Kyoto, Japan; April 15-17, 2019
EULAR: Madrid, Spain; June 12-15, 2019
This expert-led CME-certified Conference Coverage provides a comprehensive review of key data on the management of RA from 2019 APLAR, EULAR, and JCR.
Stanley B. Cohen, MD
Jonathan Kay, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 19, 2019 Expiration: August 18, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify key findings from real-world experience in the management of TNF inhibitor–refractory patients with RA
  • Describe outcomes from RA studies of biologic and targeted DMARD therapy initiated early in the disease course
  • Summarize clinical trial results and potential applications of emerging therapies for RA

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Lilly
Sanofi Genzyme and Regeneron Pharmaceuticals

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Stanley B. Cohen, MD, has disclosed that he has received consulting fees and funds for research support from AbbVie, Amgen, Gilead Sciences, Lilly, and Pfizer.
Jonathan Kay, MD

Professor of Medicine and Population & Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Physician
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Jonathan Kay, MD, has disclosed that he has he has received consulting fees from AbbVie, Boehringer Ingelheim, Celltrion, Horizon, Kolon TissueGene, Merck Sharp and Dohme, MorphoSys, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, and Union Chimique Belge and funds for research support from Gilead Sciences, Pfizer, and Union Chimique Belge.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.
Joy Curzio

Editorial Contributor

Joy Curzio has disclosed that she has ownership interests in Advaxis, Editas, and OnoSec.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with RA.

Goal

The goal of this activity is to arm clinicians with the most current clinical and scientific advances in RA so that they can apply the latest evidence to optimally manage patients and achieve treatment goals.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 19, 2019, through August 18, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Clinical Care Options commentary: Jasvinder Singh provides expert guidance on the use of newer biologic and targeted synthetic DMARDs as monotherapy for rheumatoid arthritis.

Jasvinder Singh, MD, MPH Released: August 2, 2018

Expert physician, nurse, and pharmacist views on using monotherapy to treat rheumatoid arthritis are provided in this CME/CE/CPE-certified video.

Jonathan Scott Coblyn, MD
Program Director
Jessica Farrell, PharmD Frances Griffin, RN, BSN
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 29, 2018 Expiration: June 28, 2019

Expert commentary from Roy Fleischmann, MD, on when to select biologic or targeted synthetic DMARD monotherapy for treating rheumatoid arthritis.

Roy Fleischmann, MD Released: June 8, 2018

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?